⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10661947 | 0.92 | — | — | |
| SCHEMBL31370471 | 0.89 | — | — | |
| SCHEMBL14870666 | 0.89 | — | — | |
| SCHEMBL9807363 | 0.89 | — | — | |
| SCHEMBL361297 | 0.81 | — | — | |
| SCHEMBL10932413 | 0.81 | MAPK1 (0.36) | — | |
| SCHEMBL10717480 | 0.81 | MAPK1 (0.36) | — | |
| SCHEMBL13538316 | 0.78 | MAPK1 (0.35) | — | |
| SCHEMBL12361992 | 0.78 | MAPK1 (0.35) | — | |
| SCHEMBL19193963 | 0.78 | MAPK1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720162-A1 | MAIN CHAIN CATIONIC OLIGO(IMIDAZOLIUM) FORMS N-HETEROCYCLIC CARBENE FOR EFFECTIVE BACTERIAL KILLING IN COMPLEX ENVIRONMENT | Nanyang Technological University (SG) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024248739-A1 | MAIN CHAIN CATIONIC OLIGO(IMIDAZOLIUM) FORMS N-HETEROCYCLIC CARBENE FOR EFFECTIVE BACTERIAL KILLING IN COMPLEX ENVIRONMENT | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2024-12-05 | — | — | WO | disclosed |
| EP-3577118-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2024-09-04 | — | — | EP | disclosed |
| US-10442804-B2 | Compounds for the treatment of hepatitis B virus infection | GILEAD SCIENCES, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180251460-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. | 2018-09-06 | — | — | US | disclosed |
| WO-2018144605-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2018-08-09 | — | — | WO | disclosed |
| EP-2268273-B1 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON PHARMACEUTICALS INC (US) | 2017-06-28 | — | — | EP | disclosed |
| US-9388112-B2 | Bisphenol derivatives and their use as androgen receptor activity modulators | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-07-12 | — | — | US | disclosed |
| US-9388112-B2 | Bisphenol derivatives and their use as androgen receptor activity modulators | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-07-12 | — | — | US | disclosed |
| US-20140248263-A1 | BISPHENOL COMPOUNDS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-09-04 | — | — | US | disclosed |
| WO-2007095340-A2 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY | DENDREON CORPORATION (US) | 2007-08-23 | — | — | WO | disclosed |
| US-6858679-B2 | Compositions providing improved functionalization of terminal anions and processes for improved functionalization of terminal anions | FMC CORPORATION (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1028982-B1 | COMPOSITIONS PROVIDING IMPROVED FUNCTIONALIZATION OF TERMINAL ANIONS AND PROCESSES FOR IMPROVED FUNCTIONALIZATION OF TERMINAL ANIONS | FMC CORP (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030153693-A1 | Compositions providing improved functionalization of terminal anions and processes for improved functionalization of terminal anions | QUIRK RODERIC PAUL (US) | 2003-08-14 | — | — | US | disclosed |
| US-6605564-B1 | Anionic polymerization initiators and salt additives selected from sodium chloride, sodium iodide, potassium chloride, potassium t-butoxide, for increasing the efficiency of reactions between living polymer anions and electrophiles | FMC CORPORATION | 2003-08-12 | — | — | US | disclosed |
| US-6545103-B2 | Living polymers | FMC CORPORATION | 2003-04-08 | — | — | US | disclosed |
| US-20020010082-A1 | Compositions providing improved functionalization of terminal anions and processes for improved functionalization of terminal anions | FMC CORPORATION | 2002-01-24 | — | — | US | disclosed |
| EP-1028982-A1 | COMPOSITIONS PROVIDING IMPROVED FUNCTIONALIZATION OF TERMINAL ANIONS AND PROCESSES FOR IMPROVED FUNCTIONALIZATION OF TERMINAL ANIONS | FMC CORPORATION (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999025740-A1 | COMPOSITIONS PROVIDING IMPROVED FUNCTIONALIZATION OF TERMINAL ANIONS AND PROCESSES FOR IMPROVED FUNCTIONALIZATION OF TERMINAL ANIONS | FMC CORPORATION (US) | 1999-05-27 | — | — | WO | disclosed |
| US-4725620-A | 2H-pyran-2,6-(3H)-dione derivatives with anti-allergic activity | ALLERGAN, INC. (US) | 1988-02-16 | — | — | US | disclosed |